Friday, July 10, 2026

pharma · high blood pressure · increased blood clotting

APREMEDA s.r.o

s.r.o is a pharma organization headquartered in EU. Primary therapeutic focus areas include high blood pressure, increased blood clotting, Stable Ischemic Heart Disease. NovaPharmaNews links 5 clinical program(s), 0 drug

EU HQ
2020 Founded
18 Employees
EMA registrant Type
Company details
Status
Public
HQ
EU
Founded
2020
Employees
18
Programs
5
Drugs
16
Patents
0
Clinical program

CPA 556-24

Phase 1 · other · healthy subjects, It is used in conditions with decreased immunity to enhance it e.g. in case of recurrent and chronic viral infections.

CPA 556-24 for healthy subjects, It is used in conditions with decreased immunity to enhance it e.g. in case of recurrent and chronic viral infections. is a Phase 1 program (other) at s.r.o. with 1 ClinicalTrials.gov record(s).

← All s.r.o. projects Phase 1 other active

Internal code CPA 556-24

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
s.r.o.
Phase
Phase 1
Modality
other
Indication
healthy subjects, It is used in conditions with decreased immunity to enhance it e.g. in case of recurrent and chronic viral infections.
Status
active
Trials
1